L Underbjerg1, T Sikjaer1, L Rejnmark1. 1. Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus C, Denmark.
Abstract
OBJECTIVE: Nonsurgical hypoparathyroidism (NS-HypoPT) and pseudohypoparathyroidism (PHP) are rare diseases, with a prevalence of 2/100.000 and 1/100.000, respectively. Only few studies on Quality of Life (QoL) among patients with Ns-HypoPT and PHP are available. We aimed to investigate the QoL among patients with Ns-HypoPT and PHP including information about education. DESIGN: A cohort study with patients identified from a previously epidemiological study. PATIENTS: Fifty seven patients with Ns-HypoPT and 30 patients with PHP. MEASUREMENTS: The well-validated questionnaires SF-36v2 and WHO-5 Well Being Index. Results compared to norm-based material, disease-specific norm-based material and patients with postsurgical HypoPT RESULTS: SF36v2 showed a significantly reduced score in all eight subdomains in patients with NS-HypoPT compared with a norm-based population. PHP patients scored lower in five subdomains. Females were more affected than males. Compared with postsurgical HypoPT, Ns-HypoPT and PHP are compatible at most domains. At the domains Physical Function, Social Function and Mental Health, Ns-HypoPT and PHP patients scored significantly lower (Pall < .05). At the Mental Component Score, patients with Ns-HypoPT had a lower score compared with postsurgical HypoPT (P < .01). The overall WHO-5 Well Being Index score was comparable between groups (P = .45). No differences were seen comparing patients with postsurgical HypoPT and Ns-HypoPT (P = .68) or postsurgical HypoPT and PHP (P = .67). A WHO-5 score below 28 indicates depression (NS-HypoPT=7; PHP=3, P = .71), whereas a score between 28-50 suggesting poor emotional well-being (NS-HypoPT=19; PHP=5, P = .13). The remaining patients scored above 50 suggesting well-being. CONCLUSION: QoL is impaired equally among patients with Ns-HypoPT and PHP.
OBJECTIVE: Nonsurgical hypoparathyroidism (NS-HypoPT) and pseudohypoparathyroidism (PHP) are rare diseases, with a prevalence of 2/100.000 and 1/100.000, respectively. Only few studies on Quality of Life (QoL) among patients with Ns-HypoPT and PHP are available. We aimed to investigate the QoL among patients with Ns-HypoPT and PHP including information about education. DESIGN: A cohort study with patients identified from a previously epidemiological study. PATIENTS: Fifty seven patients with Ns-HypoPT and 30 patients with PHP. MEASUREMENTS: The well-validated questionnaires SF-36v2 and WHO-5 Well Being Index. Results compared to norm-based material, disease-specific norm-based material and patients with postsurgical HypoPT RESULTS: SF36v2 showed a significantly reduced score in all eight subdomains in patients with NS-HypoPT compared with a norm-based population. PHP patients scored lower in five subdomains. Females were more affected than males. Compared with postsurgical HypoPT, Ns-HypoPT and PHP are compatible at most domains. At the domains Physical Function, Social Function and Mental Health, Ns-HypoPT and PHP patients scored significantly lower (Pall < .05). At the Mental Component Score, patients with Ns-HypoPT had a lower score compared with postsurgical HypoPT (P < .01). The overall WHO-5 Well Being Index score was comparable between groups (P = .45). No differences were seen comparing patients with postsurgical HypoPT and Ns-HypoPT (P = .68) or postsurgical HypoPT and PHP (P = .67). A WHO-5 score below 28 indicates depression (NS-HypoPT=7; PHP=3, P = .71), whereas a score between 28-50 suggesting poor emotional well-being (NS-HypoPT=19; PHP=5, P = .13). The remaining patients scored above 50 suggesting well-being. CONCLUSION: QoL is impaired equally among patients with Ns-HypoPT and PHP.
Authors: Kelly L Roszko; Tiffany Y Hu; Lori C Guthrie; Beth A Brillante; Michaele Smith; Michael T Collins; Rachel I Gafni Journal: J Bone Miner Res Date: 2021-10-18 Impact factor: 6.390
Authors: Markus Ketteler; Kristina Chen; Elvira O Gosmanova; James Signorovitch; Fan Mu; Joshua A Young; Nicole Sherry; Lars Rejnmark Journal: Adv Ther Date: 2021-03-11 Impact factor: 3.845
Authors: Bettina Stamm; Martina Blaschke; Lara Wilken; Deborah Wilde; Christina Heppner; Andreas Leha; Christoph Herrmann-Lingen; Heide Siggelkow Journal: JBMR Plus Date: 2022-02-01
Authors: Neil Gittoes; Lars Rejnmark; Steven W Ing; Maria Luisa Brandi; Sigridur Björnsdottir; Stefanie Hahner; Lorenz C Hofbauer; Pascal Houillier; Aliya A Khan; Michael A Levine; Michael Mannstadt; Dolores M Shoback; Tamara J Vokes; Pinggao Zhang; Claudio Marelli; John Germak; Bart L Clarke Journal: BMC Endocr Disord Date: 2021-11-20 Impact factor: 2.763
Authors: F Saponaro; G Alfi; F Cetani; A Matrone; L Mazoni; M Apicella; E Pardi; S Borsari; M Laurino; E Lai; A Gemignani; C Marcocci Journal: J Endocrinol Invest Date: 2022-06-25 Impact factor: 5.467